Given the ongoing extensive research on prostate cancer–associated membrane proteins such as Prostate Specific Membrane Antigen (PSMA), these strategies have strong potential to be translated into therapies for inhibiting prostate cancer metastasis, supported by in vitro, in vivo, and clinical observations [112,113,114]. The gene discussed is FOLH1; the disease is prostate cancer.